Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
An ever better description than my observation. Good answer. I am going with your opinion stated as an opinion.
Thanks. I sold some bought some back. Sold some bought some back. Etc. The timing is just bothering me and people talk.
I am a gambler. I like some risk.
Thank you for stating it’s an opinion. I have no facts. It’s only an opinion and not a fact. Go 3 71 sine 273 is not looking good. Had to enroll more patients in Rett
Next time I will write 2_73 is not working as expected if that makes one feel better.
2_73 must not be working as expected. Period.
People leak and that’s just a reality.
Trials result information must be leaking or if you need another drug, the current one must be missing the mark. Looks negative to put another drug out before results.
Or just plan bad missling leadership at Anavex.
This is that company running a bogus trial. No ARDS patients allowed and they want to be a treatment. Don’t get Covid because they are basically saying they can’t help.
Trial exclusion.
Exclusion Criteria:
Confirmed diagnosis of ARDS
Confirmed diagnosis of bacterial pneumonia or other active/uncontrolled fungal or viral infections at screening/baseline
Known medical history of tuberculosis or a risk for tuberculosis exposure
Known history of hepatitis A, hepatitis B, hepatitis C or HIV infection
History of pulmonary alveolar proteinosis (PAP)
Requiring invasive mechanical ventilation upon hospitalization prior to randomization
Women of childbearing potential who are pregnant or breastfeeding
Known hypersensitivity to lenzilumab or any of its components
Use of anti-IL-6 therapy or any other potent immunomodulatory or immunosuppressive therapy or live vaccine within 8 weeks of randomization (corticosteroid use is permitted)
Use of GM-CSF agents (e.g., sargramostim) within prior 2 months of randomization
Expected survival < 24h in the opinion of the investigator
Patient > 85 years of age
Any condition that, in the opinion of the investigator, is likely to interfere with the safety and efficacy of the study treatment or puts the patient at unacceptably
Is this junk of a ticker still trading...no sick patients allowed?
Sharted.... Wasn’t just HGEN gas. Lol.
No volume and sellers/shorts in the market. Hope you are wearing your depends.
Profit is king. Just know when to hold them, know when to walk away, and when to get the f out.
Amateur told you those shares were going to hit the market and the impact it was going to happen.
This might get real nasty as the volume is light and the market is up big time. This is not a good value at $5. Gets more interesting in 3’s if you like craps.
I told you this was going to be a pump and dump. It was already up a lot. This story has more holes in it than the titanic.
This might be a good buy but not at no damn $5 bucks. Too much risk at $5 bucks for 11 cherry picked patients.
Buy low and dump HGEN high. Last I checked JPM is a bank and they will push junk to collect fees.
Maybe you need to read the statement a little slower. Missling has missed deadlines in the past.
Pump for HGEN still ongoing but buyers are not listening.
No placebo controlled results equals ride the pump and dump. Wait for real results and not anecdotal cherry picked patients.
Nice price move yesterday.
Trial exclusion.
Exclusion Criteria:
Confirmed diagnosis of ARDS
Confirmed diagnosis of bacterial pneumonia or other active/uncontrolled fungal or viral infections at screening/baseline
Known medical history of tuberculosis or a risk for tuberculosis exposure
Known history of hepatitis A, hepatitis B, hepatitis C or HIV infection
History of pulmonary alveolar proteinosis (PAP)
Requiring invasive mechanical ventilation upon hospitalization prior to randomization
Women of childbearing potential who are pregnant or breastfeeding
Known hypersensitivity to lenzilumab or any of its components
Use of anti-IL-6 therapy or any other potent immunomodulatory or immunosuppressive therapy or live vaccine within 8 weeks of randomization (corticosteroid use is permitted)
Use of GM-CSF agents (e.g., sargramostim) within prior 2 months of randomization
Expected survival < 24h in the opinion of the investigator
Patient > 85 years of age
Any condition that, in the opinion of the investigator, is likely to interfere with the safety and efficacy of the study treatment or puts the patient at unacceptably high risk from the study
Trial exclusion is reason not to trust company or results.
“Any condition that, in the opinion of the investigator, is likely to interfere with the safety and efficacy “
Caveat emptor. Covid is an ARDS illness and in HGENs clinical trial, the very first exclusion criteria is any and all confirmed ARDS patients. Lol. https://clinicaltrials.gov/ct2/show/NCT04351152?term=Hgen&draw=2&rank=1 Martin S? Production?
What do you call a covid clinical trial that excludes patients with ARDS? Another company that will actually treat all patients.
Any condition that, in the opinion of the investigator, is likely to interfere with the safety and efficacy of the study treatment or puts the patient at unacceptably high risk from the study.
This is the last line of exclusion criteria. That’s called stacking the deck.
Watch for covid scams.
Caveat emptor. Covid is an ARDS illness and in HGENs clinical trial, the very first exclusion criteria is any and all confirmed ARDS patients. Lol.
https://clinicaltrials.gov/ct2/show/NCT04351152?term=Hgen&draw=2&rank=1
Martin S? Production?
Vaccines
The U.S, government this summer plans decisive Phase III trials of coronavirus vaccine candidates from three drugmakers, a media report said.
The Wall Street Journal reported that candidate vaccines from Moderna (MRNA) -, AstraZeneca (AZN) - with Oxford University, and Johnson & Johnson (JNJ ) - will be studied.
The government plans to fund and conduct definitive studies of the vaccines, John Mascola, director of the vaccine research center at the National Institute of Allergy and Infectious Diseases, told the Journal.
Moderna’s vaccine is scheduled first, in July. Then comes the AstraZeneca/Oxford vaccine in August and J&J’s vaccine in September, he said.
That timing indicates success for researchers who are pushing their vaccines through early test phases, the Journal notes.
Meanwhile, Eli Lilly LLY may see its coronavirus treatment medicine authorized for use as soon as September if it succeeds with tests of either of its two antibody therapies, Chief Scientific Officer Daniel Skovronsky told Reuters.
When it comes to AstraZeneca’s stock, “we don’t expect the vaccine development to impact AstraZeneca’s valuation, as the firm expects to deliver the vaccine on a non-profit basis,” Morningstar analyst Damien Conover wrote in a report last month.
“Also, government contributions will fund a heavy amount of the development and manufacturing expenses, relieving Astra of significant costs.” He maintains a wide-moat rating for the company.
One positive: “The potential vaccine could build an enormous amount of goodwill that could improve other drug-pricing negotiations, especially with governments of the world. This non-profit vaccine strategy follows a similar pathway as Johnson & Johnson,” Conover said.
AstraZeneca American depositary receipts on Wednesday closed at $53.64, up 1.7%. Johnson & Johnson shares closed at $147.72, up 1.2%. And Moderna shares closed at $60.07, up 3.2%.
Over the past three months J&J stock has risen 8%, AstraZeneca has gained 19% and Moderna has more than doubled.
Lilly stock closed at $151 on Wednesday, up 1.3%.
Point remains the same. He she it him or her. Brokerage is two way regardless. They buy and sell.
Yep and he has bought and sold investments too. Brokerage is the buying AND selling last I checked. HGEN can be bought and sold.
Hum. strength of results. Is that a guarantee? I’m holding shares of Anavex and just checking for any money back guarantees. Best wishes to the Anavex Parkinson’s patients.
I’m still not convinced by AD results of 2-73.
Headlines sells shares. Money can be made here like other pumps we have seen. I got in Moderna, Meso, and a few others and did good. It is not required for Profit and long term efficacy to reside together. Stocks can accelerate from phase 2 or compassionate results and fail in a later phase.
Profit is king. Just know when to hold them, know when to walk away, and when to get the f out.
Covid does present as a respiratory illness and when a phase 3 excludes patients with the respiratory illness that we are trying to address, that should alarm Lenzilumab investors. It’s a let’s try to profit pump.
Inclusion criteria matters and so far, we have the most inclusive. Bring me your sick.
MWM get that junk lenzilumab out of here. The first patient they exclude from their trial are patients with ARDS. Lol.
Read Cytodyns trial exclusions.
That junk you are promoting is not in the same league. Trial inclusions matter in trials.
The independent doctors support the MOA, that’s the point.
I am no expert when it comes to biotechs. But imo the results we have seen from the independent parties favoring the MOA of Leronlimab are superior to Lenzilumab. Lenzilumab patient population is not as severe as leronlimab and if you can treat the most critical you can treat the less severe cases lenzilumab targets.
HIV drug makes sense. CV targets immune system. | South China Morning Post https://www.scmp.com/news/china/society/article/3079443/coronavirus-could-target-immune-system-targeting-protective
Leron multi modal
https://m.marketscreener.com/CYTODYN-INC-163210/news/CytoDyn-Inc-Blood-Samples-at-Day-0-3-and-7-for-Severely-Ill-COVID-19-Patients-Clearly-Indicate-30395698/
Patient recruitment
Patients are often willing to consent to participation in a clinical trial if they believe that they have an opportunity to receive better treatment or if the results can help others.
Slow Anavex enrollment in multiple indications is not a good sign.
Anavex is synonymous with scams are us.
Slow enrollment is a horrible sign for Anavex. The company has support from Rett organization and enrollment still suffers. It appears doctors are not promoting these trial for some reason. Another failure.
Scamavex is what the internet has been calling the company for years instead of Anavex. It’s on scams r us.
The data in that post was assembled in 2009. I’m going to make a wild guess and say life expectancy has improved for everyone until 2020.
It appears per Parkwest Anavex is no longer “undervalued” see last line.
Park West's Event-Driven strategy involves investing their clients in stocks and/or bonds that are expected to change in price over a short period of time due to significant corporate events such as mergers, restructurings (e.g., spin-offs, acquisitions, recapitalizations and bankruptcy reorganizations), stock buybacks, bond upgrades and earnings surprises.Their Credit/High Yield strategy focuses on investments in non-investment grade debt, primarily for the purpose of acquiring undervalued instruments.
Opinions stated as fact.
Fact they dumped Anavex and bought other health related company.
Just like the rest of the world ignores Anavex worthy of being ignored.
Yep and Park west and others don’t think the risk is worth staying around for. Maybe there phones reach Spain or other countries too.
No that don’t have phones or people in other countries to check in on a small investment for them. Can’t risk doubling or tripling Park West money. No they don’t want to make money for clients.
Park west is gone. Anavex garbage is not worth the risk a few weeks from readout.
Fact. They are gone.
Opinion. Others probably left too as price dropped this quarter.